Item | Time | ||||
Baseline | 12 weeks | 26 weeks | 40 weeks | 52 weeks | |
Informed consent | • | ||||
Patient characteristics | • | ||||
SpO2 | • | • | • | • | • |
6-min walk test | • | • | • | • | • |
Endurance time | • | • | • | • | |
SGRQ and CAT | • | • | • | • | |
Dyspnoea-12 | • | • | • | • | |
HADS | • | • | • | • | |
Pedometer | • | • | • | • | |
Pulmonary function test | • | • | • | • | • |
ECG | • | • | • | • | • |
Nintedanib medication diary | • | During the study period | |||
Adverse events | During the study period |
SpO2: oxygen saturation measured by pulse oximetry; SGRQ: St George's Respiratory Questionnaire; CAT: COPD Assessment Test; HADS: Hospital Anxiety and Depression Scale.